LIFTING PLATELETS FOR ADULTS WITH CHRONIC ITP1

Doptelet is the only TPO-RA that offers a fast and durable platelet response without dietary restrictions, liver monitoring, or treatment injections.1-3*†‡§

When first-line treatments fall short, TPO-RAs step in

For adults with chronic immune thrombocytopenia (ITP), a condition characterized by increased platelet destruction and impaired platelet production, second-line treatments can be considered when first-line treatments are no longer effective. TPO-RAs like Doptelet activate the TPO receptor to increase platelet production and help manage chronic ITP. Doptelet is not used to make platelet counts normal.1,4II

Scroll left and right to view the full chart.

The safety of Doptelet has been studied in a combined 7+ years across at least 17,000 adult and pediatric patients1,7-14¶

Why choose a TPO-RA to treat ITP?

Approved for patients with chronic ITP who failed first-line therapies (corticosteroids or IVIG)1,4II
Recommended as second-line therapy by the American Society of Hematology (ASH)4II
Supported for use after initial therapy in the International Consensus Report for primary ITP15

The ASH guidelines recommend a short course of ≤6 weeks of steroids when prescribing for newly diagnosed adults with ITP.4

Could Doptelet be right for your patients?

Explore real case profiles and see how HCPs approach these same cases in the Platelet Couch video series.

What makes Doptelet different

ASH guidelines recommend selecting treatment options that align with patient preferences, which can play a key role in adherence.4

Doptelet Food Icon

No food-type restrictions

Patients can take Doptelet with any food (food required); no administration concerns with minerals like calcium or magnesium.1

No liver monitoring or cataract precautions

Doptelet does not require additional liver function monitoring or eye exams before or during treatment. No significant hepatotoxicity was seen in clinical trials.1,8,16

No injections Icon

No treatment injections

Doptelet is an oral medication that can be taken anytime, anywhere—without adding trips to the doctor.1‡

Remember to monitor drug interactions and platelet response.1‡

Doptelet was well tolerated with a safety profile comparable to placebo across multiple studies when adjusted for the duration of exposure.

To learn more about the Doptelet Safety Profile, click here.1,8

*The major efficacy outcome in this trial was the cumulative number of weeks in which the platelet count was ≥50×109/L during the 6-month treatment period in the absence of rescue therapy. 66% of patients treated with Doptelet were able to achieve a platelet count of ≥50×109/L in as few as 8 days.1 
†Doptelet-treated patients had a longer duration of platelet counts ≥50×109/L in the absence of rescue therapy than those who received placebo (12.4 median weeks vs 0 median weeks) (P<0.0001).1
‡Platelet monitoring required. After initiating therapy with Doptelet tablets, assess platelet counts weekly until a stable platelet count greater than or equal to 50×109/L has been achieved, and then obtain platelet counts monthly thereafter. Obtain platelet counts weekly for at least 4 weeks following discontinuation of Doptelet. Doptelet is not used to make platelet counts normal.1
§Doptelet must be taken with food.1
IIDoptelet was not studied as part of the 2019 ASH guidelines.4
Study approval years: Doptelet CLD, 2018; Doptelet adult ITP, 2019; Doptelet pediatric ITP, 2025.9–11

JAK-STAT=Janus kinase-signal transducer and activator of transcription; TPO=thrombopoietin.

How Doptelet works

Doptelet stimulates platelet production without blocking native TPO.1

  • Doptelet is an oral TPO-RA that binds to the c-Mpl (TPO) receptor on hematopoietic stem cells1,5,16
  • Its binding site is distinct from endogenous TPO and other TPO-RAs, activating different signal transduction pathways1,5,16 
  • This results in JAK-STAT pathway activation, megakaryocyte maturation, and increased platelet production1,5,16
  • Because it doesn’t compete with native TPO, Doptelet allows for an additive effect on platelet counts1,16
  • This differentiated signaling profile may offer an alternative approach for patients transitioning from other TPO-RAs16

Watch Video

Mechanism of action

Where would you like to go next?

I'm interested in the clinical profile of Doptelet

I'm considering Doptelet for my adult patients with chronic ITP

VIEW EFFICACY 

I’m reviewing how to dose Doptelet

I’m reviewing how to dose Doptelet

SEE DOSING 

I’m looking for access and financial support information

I’m starting a patient on Doptelet and looking for patient and financial support

EXPLORE ACCESS 

I’m looking to prescribe Doptelet or Doptelet Sprinkle for a pediatric patient

EXPLORE pediatric EFFICACY

  1. DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc; 2025.
  2. Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; 2025. 
  3. Promacta (eltrombopag) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023. 
  4. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
  5. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16.  
  6. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829-2835. 
  7. Data on file. June 3, 2025: Sobi, Inc.
  8. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
  9. FDA approves avatrombopag for thrombocytopenia in adults with chronic liver disease. U.S. Food & Drug Administration. May 21, 2018. Accessed July 24, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-thrombocytopenia-adults-chronic-liver-disease
  10. Sobi announces FDA acceptance of new drug application for avatrombopag (DOPTELET®) for the treatment of pediatric immune thrombocytopenia. News release. Biospace. December 12, 2024. Accessed July 24, 2025. https://www.biospace.com/press-releases/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet-for-the-treatment-of-pediatric-immune-thrombocytopenia
  11. Fala L. Doptelet (avatrombopag) receives FDA approval for the treatment of patients with chronic immune thrombocytopenia. American Health & Drug Benefits®. Updated August 30, 2021. Accessed July 24, 2025. https://ahdbonline.com/issues/2019/2019-payers-guide-mid-year-addendum/doptelet-avatrombopag-receives-fda-approval-for-the-treatment-of-patients-with-chronic-immune-thrombocytopenia
  12. ClinicalTrials.gov. Treatment of thrombocytopenia in patients with chronic liver disease undergoing an elective procedure (NCT01972529). Accessed July 25, 2025. https://clinicaltrials.gov/study/NCT01972529
  13. ClinicalTrials.gov. Efficacy and safety of oral E5501 plus standard of care for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (NCT01438840). Accessed July 25, 2025. https://clinicaltrials.gov/study/NCT01438840
  14. ClinicalTrials.gov. Avatrombopag for the treatment of thrombocytopenia in pediatric subjects with immune thrombocytopenia for ≥6 months (NCT04516967). Accessed July 25, 2025. https://clinicaltrials.gov/study/NCT04516967
  15. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
  16. Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev. 2022;53:100909.